Tscan Therapeutics Inc (TCRX)

$1.04 +0.02 (1.96%)
Market Cap 54.04M
Revenue (ttm) 2.82M
Net Income (ttm) -127.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,521.28%
Debt to Equity Ratio 0.23
Volume 276,908
Avg Vol 854,010
Day's Range N/A - N/A
Shares Out 56.75M
Stochastic %K 39%
Beta 1.03
Analysts Strong Sell
Price Target $6.00

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 399 9500
Address:
830 Winter Street, Waltham, United States
JSP_Dilution_Player
JSP_Dilution_Player Dec. 4 at 5:38 PM
$IPSC $FATE $TCRX all have ASH and funds into 2027. At least one should pop by Friday or Monday
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Dec. 4 at 5:13 PM
$TCRX another bio with ASH presentation and cash into 2nd half of 2027. Also, they have KOL event for Monday 12/08.
0 · Reply
Deliver1
Deliver1 Dec. 3 at 9:33 PM
$TCRX TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities https://finance.yahoo.com/news/tscan-therapeutics-host-virtual-kol-210500147.html
0 · Reply
Deliver1
Deliver1 Dec. 2 at 10:38 PM
$TCRX December 2025 Corporate presentation - MUST READ!! https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5 Please note slide 12 is data from ASH 2024, new 2 year data will be presented at ASH 2025 Data continues to look great!, imo.
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 1 at 4:10 PM
$TCRX who else bought the cyber monday sale
1 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 28 at 4:30 AM
$TCRX not interested in hitting the bid at 1.2!!! ... I NEED 1.5+!!!
1 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 28 at 2:39 AM
$TCRX pump pump~
0 · Reply
Deliver1
Deliver1 Nov. 28 at 1:50 AM
$TCRX Now at $1.30!! whaaaat! https://finance.yahoo.com/quote/TCRX/
0 · Reply
Deliver1
Deliver1 Nov. 28 at 1:30 AM
$TCRX $1.26 on overnight!( at the moment) Happy Thanksgiving everybody! https://finance.yahoo.com/quote/TCRX/
0 · Reply
Orlandotrader
Orlandotrader Nov. 26 at 10:26 PM
$TCRX FINANCIAL SNAPSHOT Price: $1.19 | Cap: $68M | Shares: 56.7M | Cash: $169M (12m+) RSI: 31 | Momentum: -43.6% | Volume: 0.9x avg 🎯 CATALYST TSC-100, TSC-101 - (ALLOHA) - Conference Presentation at ASH 2025 on December 6, 2025 (22d) | Phase 1
1 · Reply
Latest News on TCRX
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Dec 3, 2025, 4:05 PM EST - 21 hours ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 22 days ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Nov 3, 2025, 6:30 AM EST - 4 weeks ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 17, 2025, 7:00 AM EDT - 2 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

TScan Therapeutics to Participate in Upcoming Investor Conferences

Sep 3, 2025, 7:00 AM EDT - 3 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 7:00 AM EDT - 4 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28, 2025, 7:00 AM EDT - 6 months ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 7:00 AM EDT - 7 months ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Apr 28, 2025, 4:53 PM EDT - 7 months ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 8 months ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 27, 2025, 7:00 AM EDT - 9 months ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 7, 2025, 11:31 AM EST - 9 months ago

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 7:00 AM EST - 9 months ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 7:00 AM EST - 10 months ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 18, 2025, 7:00 AM EST - 10 months ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Feb 10, 2025, 3:14 AM EST - 10 months ago

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 23, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 26, 2024, 10:09 AM EDT - 1 year ago

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics Announces Updates to its Board of Directors

Jun 14, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Updates to its Board of Directors

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 29, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

May 9, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 4:05 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 24, 2024, 11:03 AM EDT - 1 year ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 22, 2024, 5:01 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 19, 2024, 10:05 AM EDT - 1 year ago

TScan Therapeutics Announces Closing of Upsized Public Offering

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 17, 2024, 12:30 AM EDT - 1 year ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:25 PM EDT - 1 year ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 16, 2024, 4:01 PM EDT - 1 year ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 8, 2024, 8:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Feb 6, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 29, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 18, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Jan 4, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value

Dec 27, 2023, 7:00 PM EST - 2 years ago

TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Dec 9, 2023, 12:00 PM EST - 2 years ago

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

Dec 7, 2023, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

JSP_Dilution_Player
JSP_Dilution_Player Dec. 4 at 5:38 PM
$IPSC $FATE $TCRX all have ASH and funds into 2027. At least one should pop by Friday or Monday
0 · Reply
JSP_Dilution_Player
JSP_Dilution_Player Dec. 4 at 5:13 PM
$TCRX another bio with ASH presentation and cash into 2nd half of 2027. Also, they have KOL event for Monday 12/08.
0 · Reply
Deliver1
Deliver1 Dec. 3 at 9:33 PM
$TCRX TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities https://finance.yahoo.com/news/tscan-therapeutics-host-virtual-kol-210500147.html
0 · Reply
Deliver1
Deliver1 Dec. 2 at 10:38 PM
$TCRX December 2025 Corporate presentation - MUST READ!! https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5 Please note slide 12 is data from ASH 2024, new 2 year data will be presented at ASH 2025 Data continues to look great!, imo.
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Dec. 1 at 4:10 PM
$TCRX who else bought the cyber monday sale
1 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 28 at 4:30 AM
$TCRX not interested in hitting the bid at 1.2!!! ... I NEED 1.5+!!!
1 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 28 at 2:39 AM
$TCRX pump pump~
0 · Reply
Deliver1
Deliver1 Nov. 28 at 1:50 AM
$TCRX Now at $1.30!! whaaaat! https://finance.yahoo.com/quote/TCRX/
0 · Reply
Deliver1
Deliver1 Nov. 28 at 1:30 AM
$TCRX $1.26 on overnight!( at the moment) Happy Thanksgiving everybody! https://finance.yahoo.com/quote/TCRX/
0 · Reply
Orlandotrader
Orlandotrader Nov. 26 at 10:26 PM
$TCRX FINANCIAL SNAPSHOT Price: $1.19 | Cap: $68M | Shares: 56.7M | Cash: $169M (12m+) RSI: 31 | Momentum: -43.6% | Volume: 0.9x avg 🎯 CATALYST TSC-100, TSC-101 - (ALLOHA) - Conference Presentation at ASH 2025 on December 6, 2025 (22d) | Phase 1
1 · Reply
Orlandotrader
Orlandotrader Nov. 26 at 10:18 PM
$TCRX In For Data Readout Early December.
1 · Reply
Deliver1
Deliver1 Nov. 26 at 9:51 PM
$TCRX Well, at least TCRX mgmt. will have a great Thanksgiving - I'm sure it's going to be a FULL SPREAD for them! Does anyone know if the Salvation Army is having a turkey thanksgiving dinner this year? i guess we will have to get in line there. https://www.sec.gov/ix?doc=/Archives/edgar/data/1783328/000119312525300538/d41366d8k.htm
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Nov. 26 at 9:28 PM
$TCRX stock close to lows and they give out 1MM units and 800k plus in cash ? i hope this wasn't the great news people were buying in the am
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 26 at 6:57 PM
$TCRX just hold until 1.5 at least... 🥱🥱🥱
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 26 at 5:31 PM
$TCRX LFG ... That sub 0.98 entry was golden ticket!!!
0 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Nov. 26 at 1:33 PM
$TCRX someone pumped? someone heard something? we are back under a buck within an hour?
0 · Reply
TA_Kongen
TA_Kongen Nov. 26 at 1:25 PM
$TCRX Small hits here, what gives?`
2 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Nov. 22 at 3:26 AM
$TCRX kinda surprised we are in the mid 90s
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 20 at 8:46 PM
$TCRX start initial now.
0 · Reply
BillionerOfKing
BillionerOfKing Nov. 20 at 5:49 PM
$TCRX Current Stock Price: $0.98
0 · Reply
MadHatterTrades74
MadHatterTrades74 Nov. 17 at 8:56 PM
$TCRX this now almost trading at -4x cash ($3.88 per share)
1 · Reply
SQUEAKSBANDIT
SQUEAKSBANDIT Nov. 17 at 5:27 PM
$TCRX took some here under 1.10 lynx is heavy in this name at much higher prices
0 · Reply